Medical Cannabis and It’s Impact on Human Health – A Cannabis Documentary [2/4] – [HD] In this myth-shattering, information-packed Documentary – Learn from Physicians and leading researchers about Medicinal Cannabis and its demonstrated effects on human health. This game-changing movie presents the most comprehensive synopsis to date of the real science surrounding the world’s most controversial plant. Topics include: * What the consensus is from over 1500 scientific and medical trials * What conditions have been proven to benefit from medical marijuana * Its historical use as medicine dating back over 5300 years * Methods of delivery and their different advantages * Government sponsored studies intended to show Marijuana having negative effects that yielded the exact opposite results * Common myths about negative effects of Marijuana and what the research really says about these topics. Doctors: Dr. David Bearman Expert Witness Former Director of Haight Ashbury Drug Treatment Program Founder of Isla Vista Medical Clinic Member of Governor Reagan’s Inter-Agency Task Force on Drug Abuse Dr. Donald Tashkin Emeritus Professor of Medicine UCLA Medical Director of UCLA Pulmonary Function Laboratory Dr. Donald Abrams Director, Integrative Oncology Research Program Integrative Medicine Physician. Professor of Clinical Medicine at UCSF and Chief of Hematology/Oncology at San Francisco General Hospital Dr. Robert Sterner UCSD General Surgeon Graduate of Harvard & UCLA Certified in Oriental and Traditional Chinese Medicine Credits: * James Schmachtenberger …

We Cannot Afford Another Lost Generation

Filed under: drug treatment programs in san francisco

He tells the assembly about a San Francisco community health seminar he attended at the time, and how the room erupted in beeps when 4, 8 and 12 o'clock rolled around because people had to take the drug in four hour intervals. "There were … Then I …
Read more on Huffington Post

Rigel dips on weak rheumatoid arthritis drug trial results

Filed under: drug treatment programs in san francisco

South San Francisco-based Rigel (NASDAQ: RIGL) said early results from a 280-patient Phase IIb study of fostamatinib did not match the effectiveness of Abbott Laboratories' (NYSE: ABT) Humira, or adalimumab, after six months of treatment. Rigel stock …
Read more on Bizjournals.com (blog)